Suven Pharma MD on selling 50% stake to Advent, open offer & running the business
“It is business as usual and it will be done by us. They are taking this to increase their bandwidth and also for us to develop the revenues and will be EPS accretive. All these things will come and create value for us and to the shareholders and mainly the customers who will get more offerings from our platforms.”
